Human BioSciences

Executive Summary

Human BioSciences (HBS) is a San Diego-based private medical device company specializing in collagen-based advanced wound care and regenerative medicine. Founded in 1999, HBS leverages its proprietary Kollagen™ technology to develop, manufacture, and market a portfolio of FDA-cleared products, including gels, sheets, and powders for chronic wounds and burns. The company also offers contract manufacturing and private labeling services, positioning it as a versatile partner in the wound care space. With an established regulatory track record and a focus on collagen's natural healing properties, HBS addresses a growing market driven by aging populations and rising rates of diabetes and chronic ulcers. While the company operates in a competitive segment dominated by larger players, its niche expertise and flexibility in manufacturing provide a differentiated value proposition. However, as a private entity with limited public disclosures, financial performance and pipeline details remain opaque. The company's long-term growth hinges on expanding its product line, securing larger distribution agreements, and capitalizing on the increasing shift toward regenerative approaches in wound management.

Upcoming Catalysts (preview)

• TBDFDA clearance for next-generation collagen-based wound matrix70% success
• Q3 2026Strategic partnership with a major hospital group for distribution50% success
• TBDPrivate label agreement with a top-tier medical supplies distributor60% success